Literature DB >> 10450505

CD30 prevents T-cell responses to non-lymphoid tissues.

W R Heath1, C Kurts, I Caminschi, F R Carbone, J F Miller.   

Abstract

Self antigens can induce T-cell tolerance via a mechanism termed cross-tolerance. This involves the transfer of peripheral tissue antigens to professional APC for presentation in the draining lymph nodes. In this site, CD8+ T cells are activated, proliferate, and are slowly deleted by a CD95-dependent mechanism. Prior to their deletion, some activated cells leave the lymph nodes and encounter antigens on peripheral parenchymal tissues. Without functional CD30, these cells proliferate extensively and cause substantial tissue damage. Thus, CD30 limits autoreactivity, acting as a 'brake' on T-cell proliferation after recognition of autoantigens on parenchymal tissues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450505     DOI: 10.1111/j.1600-065x.1999.tb01303.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  5 in total

1.  Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.

Authors:  A Cerutti; A Schaffer; R G Goodwin; S Shah; H Zan; S Ely; P Casali
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

Review 2.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

3.  Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

Authors:  K A Blum; S-H Jung; J L Johnson; T S Lin; E D Hsi; D M Lucas; J C Byrd; B D Cheson; N L Bartlett
Journal:  Ann Oncol       Date:  2010-04-27       Impact factor: 32.976

4.  Macrophages present exogenous antigens by class I major histocompatibility complex molecules via a secretory pathway as a consequence of interferon-gamma activation.

Authors:  N Martín-Orozco; A Isibasi; V Ortiz-Navarrete
Journal:  Immunology       Date:  2001-05       Impact factor: 7.397

Review 5.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.